AB Science Secures Japanese Patent for Masitinib in Progressive MS Until 2041
Event summary
- AB Science received a Japanese patent (JP 7788154) for masitinib in progressive MS, valid until February 2041.
- This is the first country to grant such a patent for masitinib in progressive MS.
- Masitinib's unique mechanism targets both microglia and mast cells, distinguishing it from BTK inhibitors.
- Positive phase 2b/3 study (AB07002) showed significant reduction in disability progression in progressive MS patients.
- Phase 3 MAXIMS study (AB20009) is ongoing to confirm earlier results.
The big picture
AB Science's Japanese patent for masitinib in progressive MS strengthens its intellectual property position in a high-unmet medical need area. The patent comes as BTK inhibitors, a competing class of drugs, have faced regulatory hurdles and efficacy challenges. This development positions masitinib as a potential first-in-class treatment targeting the innate immune system in progressive MS, which affects approximately 50% of all MS cases.
What we're watching
- Global Patent Strategy
- Whether AB Science can secure similar patents in other major markets, given its optimism for worldwide protection.
- Clinical Trial Outcomes
- The results of the ongoing phase 3 MAXIMS study and their impact on masitinib's regulatory approval prospects.
- Competitive Positioning
- How masitinib's unique mechanism of action will differentiate it from BTK inhibitors, which have faced setbacks in progressive MS.
Related topics